Meduloc, the West Chester, Pennsylvania-based orthopedic device company, has closed a $4 million Series B financing round led by GenHenn Capital to fund the commercial launch of its FDA-cleared fracture fixation platform. The round brings in a mix of institutional and individual backers, including former Los Angeles Dodgers outfielder Andre Ethier, and clears the way for Meduloc to begin a controlled alpha launch with select orthopedic surgeons and institutions starting this month. “Closing this financing is a significant milestone for Meduloc as we move from product development and regulatory clearance into controlled commercialization,” said President and CEO Sarah Sachinis.
What the Device Actually Does
Meduloc’s system centers on a flexible nitinol intramedullary implant paired with a deployable prong locking mechanism, a sterile, single-use device intended to stabilize long-bone fractures in both adult and pediatric patients while preserving surrounding anatomy. One distinguishing feature is the option to avoid entering through the joint capsule during implantation, an approach the company says can support earlier mobility, fewer complications, and a less complex surgery compared to more traditional fixation hardware. The FDA cleared the device under a 510(k) pathway in November 2025, roughly nine months before this financing, for use in metacarpal, radius, ulna, clavicle, and fibula fractures. Sachinis described the origin of the technology plainly in that earlier announcement: “An orthopedic surgeon came to us with a problem, and we developed a solution.”
A Lead Investor With Its Own Life Sciences Focus
GenHenn Capital, a single-family office venture fund based in Cranbury, New Jersey that concentrates on early and seed-stage biotech, healthcare, and life sciences companies, led the round. Bill Hagaman of GenHenn Capital pointed to Meduloc’s combination of regulatory progress and clinical traction as the reason for the firm’s confidence: “Meduloc has developed a differentiated technology with the potential to address important needs in fracture fixation. With FDA clearance, encouraging early clinical experience and an experienced team, the company has reached an exciting inflection point.” Ethier, who joined the round as an individual investor, framed his interest in personal terms: “As a former professional athlete, I have seen how injuries and recovery can affect both performance and quality of life. Meduloc’s approach stood out to me because of its potential to provide surgeons with an innovative treatment option and help patients return to the activities that matter to them.”
The Round Leans Heavily on Pennsylvania’s Own Life Sciences Investors
Beyond GenHenn Capital, the round drew participation from Life Sciences Greenhouse Investments, a Central Pennsylvania-focused life sciences investor, and from Ben Franklin Technology Partners of Southeastern Pennsylvania and Broad Street Angels, both of which invest specifically in early-stage companies within the Greater Philadelphia region where Meduloc is headquartered. Sachinis called out that regional backing directly: “We are extremely grateful for the confidence and support of our investors, and particularly proud of the strong backing we have received from the Greater Philadelphia and Pennsylvania life sciences and investment communities.” With the new capital in hand, Meduloc says it can begin building clinical experience through its alpha launch and lay the groundwork for broader adoption across adult and pediatric fracture care, the next real test for a device that’s now moved from FDA clearance into surgeons’ hands.
